---
title: "Onconetix to implement 1-for-10 reverse stock split May 21"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286909251.md"
description: "Onconetix will implement a 1-for-10 reverse stock split effective May 21, 2026, to comply with Nasdaq’s $1 minimum bid price requirement. Outstanding shares will decrease from approximately 11.4 million to about 1.14 million, with fractional shares canceled and cash paid based on the previous day's closing price. The Nasdaq ticker will remain ONCO."
datetime: "2026-05-19T12:07:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286909251.md)
  - [en](https://longbridge.com/en/news/286909251.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286909251.md)
---

# Onconetix to implement 1-for-10 reverse stock split May 21

-   Onconetix will implement a 1-for-10 reverse stock split effective 12:01 a.m. ET on May 21, 2026. \* Shares are set to trade on a split-adjusted basis at the market open on May 21, 2026, with the Nasdaq ticker unchanged as ONCO. \* The move targets compliance with Nasdaq’s $1 minimum bid price requirement. \* Outstanding shares are expected to fall to about 1,140,000 from about 11,400,000. \* Fractional shares will be canceled, with cash paid based on the prior trading day’s closing price. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190800PRIMZONEFULLFEED9722785) on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis](https://longbridge.com/en/news/286903126.md)
- [Nexalin closes acquisition of PONM digital health platform for USD 1.3 million](https://longbridge.com/en/news/286912786.md)
- [RenovoRx (RNXT) Q1 2026 Earnings Transcript](https://longbridge.com/en/news/286914537.md)
- [Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS](https://longbridge.com/en/news/286899373.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)